Last reviewed · How we verify
Glatiramer Acetate, N-Acetylcysteine
Glatiramer Acetate, N-Acetylcysteine is a Small molecule drug developed by Teva Branded Pharmaceutical Products R&D, Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | Glatiramer Acetate, N-Acetylcysteine |
|---|---|
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glatiramer Acetate, N-Acetylcysteine CI brief — competitive landscape report
- Glatiramer Acetate, N-Acetylcysteine updates RSS · CI watch RSS
- Teva Branded Pharmaceutical Products R&D, Inc. portfolio CI
Frequently asked questions about Glatiramer Acetate, N-Acetylcysteine
What is Glatiramer Acetate, N-Acetylcysteine?
Glatiramer Acetate, N-Acetylcysteine is a Small molecule drug developed by Teva Branded Pharmaceutical Products R&D, Inc..
Who makes Glatiramer Acetate, N-Acetylcysteine?
Glatiramer Acetate, N-Acetylcysteine is developed by Teva Branded Pharmaceutical Products R&D, Inc. (see full Teva Branded Pharmaceutical Products R&D, Inc. pipeline at /company/teva-branded-pharmaceutical-products-r-d-inc).
What development phase is Glatiramer Acetate, N-Acetylcysteine in?
Glatiramer Acetate, N-Acetylcysteine is in Phase 2.